Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2011-12-20

FDA Approved: EDARBYCLOR — Original Application (Azurity Pharmaceuticals, Inc. (formerly Arbor Pharmaceuticals))

View source ↗

Summary

FDA approved EDARBYCLOR, a fixed-dose combination of azilsartan medoxomil and chlorthalidone, under an original NDA. The approval was granted to Azurity Pharmac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EDARBYCLOR (AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE)

Snippet

ORIG AP for EDARBYCLOR (AZILSARTAN KAMEDOXOMIL AND CHLORTHALIDONE)